Summary for Tradename: GLEEVEC
Clinical Trials for: GLEEVEC
Pilot Study of Gleevec/Imatinib Mesylate (STI-571, NSC 716051) in Neurofibromatosis (NF1) Patient With Plexiform Neurofibromas
Status: Active, not recruiting Condition: Neurofibromatosis; Neurofibromas
Glivec/Gleevec Pediatric (Age 1 to Less Than 4) PK Study in CML, Ph+ ALL Patients and Other Glivec/Gleevec® Indicated Hematological Disorders.
Status: Terminated Condition: Chronic Myeloid Leukemia (CML); Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL); Other Glivec/Gleevec Indicated Hematological Disorders (HES, CEL, MDS/ MPN)
Study to Allow Access to Imatinib for Patients Who Are on Imatinib Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator
Status: Recruiting Condition: GIST and CML
Therapy of Early Chronic Phase CML With Gleevec
Status: Completed Condition: Leukemia, Myeloid, Chronic-Phase
Dose Escalation Study of Gleevec and Chlorambucil in Previously Treated Chronic Lymphocytic Leukemia Patients
Status: Terminated Condition: Chronic Lymphocytic Leukemia
Effect of Antacids on Gleevec® in Healthy Volunteers
Status: Completed Condition: Healthy
Proof of Concept Trial of Gleevec (Imatinib) in Active Diffuse Scleroderma
Status: Terminated Condition: Scleroderma
Ph I Gleevec in Combo w RAD001 + Hydroxyurea for Pts w Recurrent MG
Status: Completed Condition: Glioblastoma; Gliosarcoma
Zarnestra and Gleevec in Chronic Phase Chronic Myelogenous Leukemia
Status: Completed Condition: Leukemia, Myeloid, Chronic
Study of Hyper-CVAD Plus Imatinib Mesylate for Philadelphia-Positive Acute Lymphocytic Leukemia
Status: Completed Condition: Leukemia
Courtesy of ClinicalTrials.org
See more clinical trials for this drug
|Applicant||Tradename||Generic Name||Dosage||NDA||Approval Date||Type||RLD||Patent No.||Patent Expiration||Product||Substance||Delist Req.||Exclusivity Expiration|
|CAPSULE;ORAL||021335||May 10, 2001||DISCN||No||5,521,184*PED||<disabled>||Y||<disabled>|
|CAPSULE;ORAL||021335||May 10, 2001||DISCN||No||6,894,051*PED||<disabled>||Y||<disabled>|
|CAPSULE;ORAL||021335||May 10, 2001||DISCN||No||6,958,335*PED||<disabled>||Y||<disabled>|
|CAPSULE;ORAL||021335||May 10, 2001||DISCN||No||RE43932*PED||<disabled>||<disabled>|
|This preview shows a limited data set|
Complete access is available with a Subscription
Export unavailable in trial.
Subscribe for complete access.
|imatinib mesylate||Tablets||100 mg and 400 mg||Gleevec||3/12/2007|
|imatinib mesylate||Capsules||400 mg||Gleevec||1/24/2014|
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639